Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer

International Journal of Cancer

Volumn 84, Issue 4, 1999, Pages 421-425

  Morote, Joan ^a   De Torres, Inés ^a   Caceres, Carme ^a   Vallejo, Carlos ^a   Schwartz Jr , Simó ^a   Reventos, Jaume ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; DISEASE MARKER; GENE EXPRESSION SYSTEM; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOPSY; BONE NEOPLASMS; FOLLOW-UP STUDIES; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0032794761     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990820)84:4<421::AID-IJC16>3.0.CO;2-9     Document Type: Article

References (21)

1. ARAI, Y., YOSHIKI, T. and YOSHIDA, O., c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate, 30, 195-201 (1997).
2. BOSTWICK, D.G. and AQUILINA, J.W., Prostatic intra-epithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials. J. cell. Biochem. (Supp.), 25, 156-164 (1996).
3. COFFEY, D.S., Prostate cancer. Cancer (Supp.), 71, 880-886 (1993).
4. FENDLY, B.M., KOTTS, C., VETTERLEIN, D., LEWIS, G.D., WINGET, M., CARVER, M.E., WATSON, S.R., SARUP, J., SAKS, S. and ULLRICH, A., The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J. biol. Response Mod., 9, 449-455 (1990).
5. FLEMING, W.H., HAMEL, A., MACDONALD, R., RAMSEY, E., PETTIGREW, N.M., JOHNSTON, B., DODD, J.G. and MATUSIK, R.J., Expression of the c-myc proto-oncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res., 46, 1535-1538 (1986).
6. GU, K., MES-MASSON, A.M., GAUTHIER, J. and SAAD, F., Over-expression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett., 99, 185-189 (1996).
7. HALE, R., BUCKLEY, C., FOX, H. and WILLIAMS, J., Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J. clin. Pathol., 45, 594-596 (1992).
8. HYNES, N.E., GERBER, H.A., SAURER, S. and GRONER, B., Over-expression of the c-erbB-2 protein in human breast-tumor cell lines. J. cell. Biochem., 39, 167-173 (1989).
9. KOHUKO, M., YOSHIKI, T., HAMAGUCHI, A., OKADA, Y., TOMOYOSHI, T. and HIGUCHI, K., Immunohistochemical study of c-erbB-2 proto-oncogene product in prostatic cancer. Nippon Hinyokika Gakkai Zasshi, 84, 1872-1878 (1993).
10. KREIS, W., AHMANN, F.R., LESSER, M., SCOTT, M., CAPLAN, R., GAU, T. and VINVIGUERRA, V., Predictive initial parameters for response of stage-D prostate cancer to treatment with the luteinizing-hormone-releasing hormone agonist goserelin. J. clin. Oncol., 8, 870-874 (1990).
11. KUHN, E.J., KURNOT, R.A., SESTERHENN, I.A., CHANG, E.H. and MOUL, J. W., Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol., 150, 1427-1433 (1993).
12. LALANI, E.N., LANIADO, M.E. and ABEL, P.D., Molecular and cellular biology of prostate cancer. Cancer Metastasis Rev., 16, 29-66 (1997).
13. MELLON, K., THOMPSON, S., CHARLTON, R.G., MARSH, C., ROBINSON, M., LANE, D.P., HARRIS, A.L., HORNE, C.H. and NEAL, D.E., p53, c-erbB-2 and the epidermal-growth-factor receptor in the benign and malignant prostate. J. Urol., 147, 496-499 (1992).
14. MYERS, R.B., BROWN, D., OELSCHLAGER, D.K., WATERBOR, J.W., MARSHALL, M.E., SRIVASTAVA, S., STOCKARD, C.R., URBAN, D.A. and GRIZZLE, W.E., Elevated serum levels of p105(erbB-2) in patients with advanced-stage prostatic adenocarcinoma. Int. J. Cancer, 69, 398-402 (1996).
15. PEEHL, D.M., Oncogenes in prostate cancer. An update. Cancer, 71, 1159-1164 (1993).
16. SADASIVAN, R., MORGAN, R., JENNINGS, S., AUSTENFELD, M., VAN VELDHUIZEN, P., STEPHENS, R. and NOBLE, M., Over-expression of HER-2/NEU may be an indicator of poor prognosis in prostate cancer. J. Urol., 150, 126-131 (1993).
17. SLAMON, D.J., GODOLPHIN, W., JONES, L.A., HOLT, J.A., WONG, S.G., KEITH, D.E., LEVIN, W.J., STUART, S.G., UDOVE, J. and ULLRICH, A., Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-712 (1989).
18. STROHMEYER, T.G. and SLAMON, D.J., Proto-oncogenes and tumor-suppressor genes in human urological malignancies. J. Urol., 151, 1479-1497 (1994).
19. VELTRI, J., PARTIN, A.W., EPSTEIN, J.E., MARLEY, G.M., MILLER, C.M., SINGER, D.S., PATTON, K.P., CRILEY, S.R. and COFFEY, D.S., Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a pplCAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate-cancer progression. J. cell. Biochem. (Suppl.), 19, 249-258 (1994).
20. VISAKORPI, T., HYYTINEN, E., KOIVISTO, P., TANNER, M., KEINANEN, R., PALMBERG, C., PALOTIE, A., TAMMELA, T., ISOLA, J. and KALLIONIEMI, O.P., In vivo amplification of the androgen-receptor gene and progression of human prostate cancer. Nature Genet., 9, 401-406 (1995).
21. ZHAU, H.E., WAN, D.S., ZHOU, J., MILLER, G.J. and VON ESCHENBACH, A.C., Expression of c-erbB-2/neu proto-oncogene in human prostatic-cancer tissues and cell lines. Mol. Carcinogen., 5, 320-327 (1992).